The Canberra Hospital
Welcome,         Profile    Billing    Logout  
 22 Trials 
41 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rao, Krishna
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
MARC, NCT02324582: MK-3475/BCG in High Risk Superficial Bladder Cancer

Completed
1
18
US
Intravenous MK-3475/ Intravesical BCG, pembrolizumab
Southern Illinois University, Merck Sharp & Dohme LLC
Bladder Cancer
11/21
03/23
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
Ravani, Pietro
ACCESS HD, NCT02675569: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis

Recruiting
N/A
100
Canada, RoW
Catheter, Fistula
University of Calgary, Applied Health Research Centre, The George Institute
End-stage Kidney Failure
03/25
03/25
Brown, Karen T
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
UP-FRONT, NCT05236920: Utility and Procedural Feasibility of REBOA Operationalized for Non-Trauma Application

Withdrawn
N/A
40
NA
Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device, REBOA procedure
University of Alabama at Birmingham
Cardiac Arrest, Out-Of-Hospital, Ventricular Fibrillation, Ventricular Tachycardia
10/22
10/22
NCT01696721: Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

Recruiting
N/A
5000
US
No intervention
Massachusetts General Hospital
Pediatric Patients Treated With Radiation Therapy
12/25
12/25
Fields, Ryan
NCT04536077: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
2
16
US
CDX-301, CDX-1140, Research blood draw
Washington University School of Medicine, Celldex Therapeutics, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
11/23
11/23
NCT04412629: Cabozantinib in High Grade Neuroendocrine Neoplasms

Recruiting
2
32
US
Cabozantinib, Cabometyx, Blood for plasma biomarkers, Tissue biopsy
Washington University School of Medicine, Exelixis
High Grade Neuroendocrine Neoplasms
07/25
03/26
NCT05251233: Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

Terminated
2
56
US
Placebo, Pantoprazole
Washington University School of Medicine
Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor, Pancreatitis, Distal Extrahepatic Cholangiocarcinoma, Duodenal Cancer
06/24
06/24
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
NCT05629546: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Recruiting
1
33
US
Cytokine-induced memory-like natural killer cells, ML NK cells, CIML, Relatilmab, Opdualag, Nivolumab
Washington University School of Medicine, Melanoma Research Alliance, Rising Tide Foundation
Advanced Melanoma, Metastatic Melanoma
02/29
11/30
NCT06340646: Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Recruiting
N/A
990
US
Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues
Washington University School of Medicine, National Cancer Institute (NCI), The Foundation for Barnes-Jewish Hospital
Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
01/27
01/27
NCT00900198: Collection of Tissue Samples for Cancer Research

Recruiting
N/A
5000
Canada, US
Biopsy
National Cancer Institute (NCI)
Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
 
 
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
METEOR-CRATR, NCT05975593: MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Recruiting
N/A
60
US
Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI), DBSI MRI
Washington University School of Medicine, National Cancer Institute (NCI)
Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas
12/32
12/32
Heerspink, Hiddo J Lambers
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Recruiting
4
17
Canada
Dapagliflozin 10 MG [Farxiga]
George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
03/22
04/22
Optimize@Home, NCT06094920: Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Enrolling by invitation
4
10
Europe
Empagliflozin 10 MG, Jardiance, A10BK03, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, Finerenone, Kerendia, C03DA05, (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, Withings BPM Connect, Withings Body, PeeSpot Urine Collection Device, Hem-Col Capillary Blood Collection Device, Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
University Medical Center Groningen, Boehringer Ingelheim
Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
10/24
11/24
CAPTIVATE, NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
3
1000
RoW
Finerenone, BAY94-8862, Placebo Finerenone
The George Institute
Chronic Kidney Diseases
08/28
12/28
ZODIAC, NCT05570305 / 2021-001324-18: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Enrolling by invitation
2
38
Europe, Canada, US
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
University Medical Center Groningen, AstraZeneca
Chronic Kidney Diseases
04/24
09/24
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
NCT04389827: Global Kidney Patient Trials Network

Recruiting
N/A
6000
RoW
The George Institute, George Clinical Pty Ltd
Kidney Diseases
04/25
04/30
Yip, Desmond
ALT GIST, NCT02365441 / ACTRN12614000950662: A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Completed
2
78
Europe, RoW
Regorafenib, imatinib, Glevec
Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer - EORTC, Scandinavian Sarcoma Group
Gastrointestinal Stromal Tumour
12/23
12/23
Read, Rebecca
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
Pathak, Rajeev
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
NCT04863664: Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)

Recruiting
N/A
975
Europe, Canada, Japan, US, RoW
Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
Medtronic Cardiac Rhythm and Heart Failure
Tachyarrhythmia
06/25
02/26
STARAF3, NCT04428944: STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Recruiting
N/A
615
Europe, Canada, Japan, US, RoW
Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI), Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers), Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal Heart Institute
Atrial Fibrillation
08/26
01/27
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
03/26
03/26
CAAD-VT, NCT05524077: Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

Recruiting
N/A
162
RoW
Ablation, Anti-arrhythmic Drugs (AADs)
Western Sydney Local Health District
Heart Disease Structural Disorder, Ventricular Tachycardia, Cardiomyopathy, Dilated, Sarcoidosis, Cardiomyopathy, Hypertrophic, Cardiomyopathy Ischemic, Cardiomyopathy, Familial, Arrhythmogenic Right Ventricular Cardiomyopathy 1, Arrhythmogenic Left Ventricular Cardiomyopathy
06/26
06/26
Talaulikar, Girish S
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Calendar Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease
Recruiting
3
2000
Europe, Canada, RoW
Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo
The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
06/27
12/27
CAPTIVATE, NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
3
1000
RoW
Finerenone, BAY94-8862, Placebo Finerenone
The George Institute
Chronic Kidney Diseases
08/28
12/28
ACCESS HD, NCT02675569: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis

Recruiting
N/A
100
Canada, RoW
Catheter, Fistula
University of Calgary, Applied Health Research Centre, The George Institute
End-stage Kidney Failure
03/25
03/25
Palfreyman, Emma
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
Orefice, Roberto
PROTECTMe, NCT05651347: Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction

Recruiting
3
336
RoW
Placebo, Melatonin 10 MG
Monash University, National Health and Medical Research Council, Australia, Cerebral Palsy Alliance, Equity Trustees
Fetal Growth Retardation, Stillbirth and Fetal Death, Pregnancy Preterm
12/25
01/26
Crassini, Kyle
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
Investigator, Phillip Braslins Principal
ROADMAP, NCT06771050: Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform () Trial is an International RCT Evaluating the Effect of a Range of Clinical Surgical and Antibiotic Interventions on Treatment Success 12 Mths Post-platform Entry in Adults With Prosthetic Joint Infection (PJI)

Not yet recruiting
4
2500
RoW
Debridement and Implant Retention (DAIR), Revision Arthroplasty - Single stage revision, Antibiotic Choice, No intervention: Standard of Care "Backbone antibiotics", Intervention: Standard of care " Backbone antibiotics" + Rifampicin antibiotics, Antibiotic duration Part A - Single stage revision, shorter duration - 6 weeks, longer duration - 12 weeks, Antibiotic Duration Part B - Two stage revision, Extended antibiotic prophylaxis following 2nd stage Revision operation, No extended antibiotic prophylaxis following 2nd stage Revision operation
University of Newcastle, Australia, Hunter Medical Research Institute (HMRI), The University of Western Australia, Michael Garron Hospital, Aotearoa Clinical Trials, Exeter Orthopaedic Trial unit, University of Sydney, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
02/28
12/29

Download Options